Abbott vs. Intuitive Surgical: Which MedTech Stock Offers Better Long-Term Upside?

MedTech investors must decide between Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG). Abbott is a diversified healthcare company that expands in diagnostics, medical devices, and nutrition. Intuitive Surgical is the leader in robotic surgery with a premium valuation reflecting continued growth expectations. Both companies reported strong quarterly results, but the market reacted differently.

Abbott (NYSE:ABT) raised its annual profit outlook after another solid quarter. Its diagnostics business showed strong growth, with revenue up 42% year-over-year to $3.09 billion and the Cologuard colorectal cancer screening test benefiting from increased users. The company's medical device franchise remains a stable part of its operations.

Intuitive Surgical (NASDAQ:ISRG) relies on its robotic surgery ecosystem and recurring revenue from its da Vinci surgical systems. The installed base grew 18% year-over-year, and the company's latest da Vinci 5 platform adoption accelerated. However, market concerns focus on slowing domestic procedure growth.

Valuation-wise, Intuitive Surgical trades at a forward P/E of 35.10, an 81.88% premium to its sector, while Abbott trades at 19.54, just a 1.27% premium. Analyst price targets suggest 22.78% upside for Intuitive and 9.56% for Abbott, indicating greater appreciation potential in Intuitive, despite its higher valuation.

Institutional positioning shows more support for Abbott, with hedge fund ownership increasing slightly, while Intuitive's ownership declined. Abbott's diversified portfolio offers stability, while Intuitive remains a high-growth leader in robotic surgery. Investors must weigh the trade-off between consistent earnings growth and potential long-term upside.